Optieum Biotechnologies Inc., a biopharmaceutical company focused on developing innovative cancer immunotherapies, has secured a significant funding boost through a grant of up to $39 million from the Japanese Agency for Medical Research and Development (AMED). This substantial award, granted under AMED’s “Strengthening Program for Pharmaceutical Startup Ecosystem,” underscores the agency’s commitment to fostering cutting-edge medical research and development within Japan.
The primary objective of this funding is to accelerate the preclinical and early clinical development of Optieum’s lead CAR-T cell therapy program, OPTF01. This program is specifically designed to address glioblastoma, an aggressive and notoriously difficult-to-treat form of brain cancer. The AMED grant will provide crucial resources to support critical activities, including preclinical studies, manufacturing process optimization, and the necessary steps leading to an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA).
Shun Nishioka, Chief Executive Officer of Optieum Biotechnologies, expressed gratitude for AMED’s support, highlighting its significance in propelling the company’s mission. He emphasized that this funding, combined with the continued support from esteemed investors such as Saisei Ventures, Keio Innovation Initiative, and ANRI, will enable Optieum to rapidly advance OPTF01 toward clinical trials. This collaborative financial foundation is vital for navigating the complex and resource-intensive process of bringing novel cell therapies to patients.
Optieum’s innovative approach centers on its proprietary Eumbody System, a platform technology designed to optimize CAR (chimeric antigen receptor) constructs. This system plays a pivotal role in enhancing the therapeutic potential of T cells, the immune cells engineered to target and destroy cancer cells. By refining CAR constructs, Optieum aims to improve the efficacy, safety, and durability of its CAR-T cell therapies, ultimately offering more effective treatment options for patients battling challenging cancers like glioblastoma. This AMED grant represents a major milestone for Optieum, validating its technological approach and providing the necessary resources to translate its promising research into tangible clinical benefits.
Source:
https://optieumbio.com/39-million-grant-from-japanese-agency-for-medical-research-and-development/
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
